1. Home
  2. ATYR vs SOL Comparison

ATYR vs SOL Comparison

Compare ATYR & SOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo aTyr Pharma Inc.

ATYR

aTyr Pharma Inc.

HOLD

Current Price

$0.74

Market Cap

79.2M

Sector

Health Care

ML Signal

HOLD

Logo Emeren Group Ltd each representing 10 shares

SOL

Emeren Group Ltd each representing 10 shares

HOLD

Current Price

$1.94

Market Cap

98.5M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATYR
SOL
Founded
2005
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
79.2M
98.5M
IPO Year
2015
2008

Fundamental Metrics

Financial Performance
Metric
ATYR
SOL
Price
$0.74
$1.94
Analyst Decision
Buy
Strong Buy
Analyst Count
6
2
Target Price
$8.75
$4.50
AVG Volume (30 Days)
2.4M
270.2K
Earning Date
11-06-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$190,000.00
$71,226,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$18,728.88
$45.37
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.64
$1.04
52 Week High
$7.29
$2.30

Technical Indicators

Market Signals
Indicator
ATYR
SOL
Relative Strength Index (RSI) 39.64 68.41
Support Level $0.70 $1.89
Resistance Level $0.83 $1.95
Average True Range (ATR) 0.05 0.05
MACD 0.02 0.02
Stochastic Oscillator 22.26 96.54

Price Performance

Historical Comparison
ATYR
SOL

About ATYR aTyr Pharma Inc.

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About SOL Emeren Group Ltd each representing 10 shares

Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has globalised Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. Majority of revenue is From Electricity Generation. The company operates in China, USA, Germany, UK, Spain, France, Poland, Italy, Hungary, Luxembourg. Majority of revenue is from Italy.

Share on Social Networks: